Mark A Socinski Selected Research

Mark A Socinski Research Topics

Disease

151	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/2022 - 03/2002
70	Neoplasms (Cancer) 02/2022 - 10/2002
31	Lung Neoplasms (Lung Cancer) 01/2022 - 11/2004
27	Disease Progression 01/2021 - 09/2002
23	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2017 - 04/2003
19	Neutropenia 01/2021 - 11/2002
10	Neoplasm Metastasis (Metastasis) 01/2022 - 11/2006
10	Thrombocytopenia (Thrombopenia) 01/2018 - 10/2006
9	Adenocarcinoma of Lung 01/2021 - 11/2006
9	Carcinoma (Carcinomatosis) 01/2018 - 07/2002
8	Fatigue 01/2018 - 06/2005
8	Adenocarcinoma 01/2018 - 08/2009
8	Leukemia 01/2017 - 04/2003
7	Brain Neoplasms (Brain Tumor) 01/2022 - 09/2007
7	Anemia 01/2021 - 10/2009
7	Febrile Neutropenia 01/2020 - 04/2008
7	Exanthema (Rash) 10/2017 - 04/2005
6	Pneumonia (Pneumonitis) 06/2020 - 07/2002
5	Esophagitis 05/2013 - 10/2002
4	Peripheral Nervous System Diseases (PNS Diseases) 01/2021 - 08/2003
4	Hypertension (High Blood Pressure) 01/2020 - 04/2008
4	Hemorrhage 01/2018 - 04/2008
3	Sarcoma (Soft Tissue Sarcoma) 01/2021 - 04/2007
3	Leukopenia 01/2018 - 10/2009
3	Diarrhea 10/2017 - 11/2002
3	Nausea 10/2017 - 04/2005
3	Infections 01/2017 - 07/2002
3	Mucositis 01/2017 - 04/2005
3	Alopecia (Baldness) 12/2013 - 06/2008
2	Cough 01/2018 - 07/2002
2	Malignant Mesothelioma 11/2017 - 04/2005
2	Acne Vulgaris 07/2015 - 11/2008
2	Melanoma (Melanoma, Malignant) 02/2014 - 05/2013
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 05/2012 - 10/2010

Drug/Important Bio-Agent (IBA)

55	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 09/2002
44	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 07/2002
28	Bevacizumab (Avastin)FDA Link 02/2022 - 09/2007
24	PlatinumIBA 01/2022 - 09/2002
24	Pemetrexed (MTA)FDA Link 01/2022 - 04/2005
22	Gemcitabine FDA Link 10/2019 - 07/2002
15	ErbB Receptors (EGF Receptor)IBA 07/2022 - 08/2007
14	Docetaxel (Taxotere)FDA Link 01/2020 - 09/2002
12	Cisplatin (Platino)FDA LinkGeneric 10/2019 - 11/2002
11	Tyrosine Kinase InhibitorsIBA 07/2022 - 05/2007
11	130-nm albumin-bound paclitaxelIBA 01/2021 - 05/2008
11	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 08/2009
10	Pharmaceutical PreparationsIBA 01/2017 - 07/2002
9	Monoclonal AntibodiesIBA 02/2022 - 04/2008
9	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2010
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2022 - 02/2008
7	atezolizumabIBA 01/2022 - 06/2018
7	necitumumabIBA 10/2019 - 03/2015
7	Gefitinib (Iressa)FDA Link 01/2017 - 06/2006
7	Etoposide (VP 16)FDA LinkGeneric 01/2017 - 01/2005
7	SolventsIBA 01/2016 - 10/2007
6	Immune Checkpoint InhibitorsIBA 01/2022 - 02/2014
6	B7-H1 AntigenIBA 01/2021 - 10/2015
6	Sunitinib (Sutent)FDA Link 01/2017 - 02/2008
6	Irinotecan (Camptosar)FDA LinkGeneric 03/2008 - 10/2002
5	Albumin-Bound Paclitaxel FDA Link 01/2021 - 10/2007
5	CrizotinibIBA 10/2020 - 01/2011
5	AntibodiesIBA 01/2018 - 08/2007
4	Anaplastic Lymphoma KinaseIBA 10/2020 - 12/2014
4	NivolumabIBA 01/2017 - 01/2015
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2015 - 05/2007
4	taxaneIBA 01/2014 - 07/2002
4	Vinorelbine (Navelbine)FDA LinkGeneric 07/2008 - 06/2004
3	nintedanibIBA 01/2018 - 12/2011
3	alectinibIBA 01/2018 - 02/2016
3	LigandsIBA 10/2015 - 03/2010
3	Biological ProductsIBA 01/2015 - 11/2004
3	Proteins (Proteins, Gene)FDA Link 09/2014 - 01/2011
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 12/2011
2	AlbuminsIBA 01/2021 - 10/2012
2	Biosimilar PharmaceuticalsIBA 01/2021 - 01/2015
2	RamucirumabIBA 01/2020 - 01/2018
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 08/2017 - 10/2015
2	STA 9090IBA 05/2015 - 06/2013
2	Topotecan (Hycamtin)FDA LinkGeneric 12/2014 - 01/2005
2	pazopanib FDA Link 11/2014 - 12/2011
2	EnzymesIBA 09/2014 - 04/2005
2	AntigensIBA 02/2014 - 01/2014
2	Eosine Yellowish-(YS) (Eosin)IBA 01/2013 - 08/2009
2	Hematoxylin (Haematoxylon)IBA 01/2013 - 08/2009
2	Taxoids (Taxanes)IBA 10/2012 - 07/2002
2	Sorafenib (BAY 43-9006)FDA Link 12/2011 - 02/2011
2	Platelet-Derived Growth FactorIBA 12/2011 - 02/2008
2	Cetuximab (Erbitux)FDA Link 01/2011 - 02/2010
2	matuzumabIBA 12/2010 - 08/2007

Therapy/Procedure

84	Therapeutics 01/2022 - 03/2002
63	Drug Therapy (Chemotherapy) 01/2022 - 03/2002
23	Radiotherapy 11/2017 - 10/2002
10	Combined Modality Therapy 03/2008 - 10/2004
8	Chemoradiotherapy 11/2021 - 07/2005
7	Immunotherapy 01/2020 - 01/2014
5	Conformal Radiotherapy 11/2011 - 10/2002
4	Induction Chemotherapy 09/2017 - 03/2008
3	Duration of Therapy 07/2009 - 03/2002
2	Aftercare (After-Treatment) 01/2018 - 05/2017
2	Intravenous Infusions 06/2013 - 02/2008